Most conversations about depression care in Japan stop at stigma. That's a real barrier, and it keeps a great many people from ever naming what they're experiencing, let alone booking an appointment. But there's a second barrier, and it sits on the other side of the door.
The structural picture explains part of why that second barrier bites so hard here. Japan has markedly fewer psychiatrists relative to its population than many other wealthy countries, a gap long linked to historically low rates of seeking treatment for mental illness. With specialists thin on the ground, particularly outside the big cities, general practitioners frequently handle the initial diagnosis and the first prescription. That isn't a criticism of GPs. It's a description of where the work lands.
Look at the United States and you see a different shape to the same underlying problem. Antidepressant use among American adults climbed substantially over the past decade, according to the CDC's National Center for Health Statistics, and women are more than twice as likely as men to be taking them. Where use is that widespread, the question of whether a given drug suits a given person stops being a niche clinical concern. Our expectation is that narrowing the guesswork at the outset would matter more, not less, in a system shaped like Japan's, where a non-specialist often writes the first prescription and follow-up appointments are harder to come by.
That expectation is what the broader international push toward more precise psychiatric prescribing is built on. Pharmacogenomic testing belongs to that push, and GeneSight publishes information addressing which depression medications will work best for you.
Enduring Quietly Is Still the Default
Depression is called utsubyō in Japanese. Language matters more than it might appear. A term that only ever gets used in a clinic is a term that belongs to other people, people who are unwell in a way you are not. That makes the first act of recognising yourself in it considerably harder.
Running alongside the vocabulary problem is gaman, the cultural norm of enduring hardship without outward complaint, widely cited as a factor that discourages people from acknowledging psychological distress or seeking treatment for it. Gaman isn't a flaw. It's a virtue in most of the contexts where it's taught, and it carries people through genuinely difficult stretches of work and family life. The trouble is that it offers no way to distinguish between hardship you endure and an illness you treat. Both present as something to be borne quietly.
Which means the first barrier operates well before anyone considers medication. It operates at the point where a person decides whether what they're feeling counts as a symptom.
General Practitioners Carry a Specialist's Load
The workforce arithmetic is not improving. A study drawing on Japan's national patient survey data projects that the average number of psychiatrists available per patient with mood disorders and other major mental illnesses will be significantly lower in 2025, 2035 and 2045 than it was in 2015. That is a decline measured against need, not against population, which is the comparison that matters to anyone waiting for an appointment.
Researchers behind those projections recommend that policymakers plan to shift some clinical responsibilities from psychiatrists to other mental health workers and improve how resources are allocated geographically, specifically to offset the worsening shortage. Read that as an acknowledgement that the specialist supply isn't going to catch up on its own.
In practice, the shift has already happened informally. With specialists relatively scarce outside major cities, general practitioners in Japan often handle initial depression diagnoses and medication prescribing. When the first medication doesn't suit the patient, the follow-up conversation competes with everything else in the appointment book.
A Cold of the Soul Changed the Vocabulary
Public-education efforts that began around the time SSRIs became available in Japan used the phrase kokoro no kaze, a cold of the soul, to present depression as an ordinary and treatable illness rather than a personal failing. It was a clever reframing. A cold is something anyone catches, nobody chooses, and most people recover from with treatment.
Policy followed. In 2013, Japan's Ministry of Health, Labour and Welfare designated mental illness as the fifth priority disease for national medical care planning, which obliged every prefecture to start drawing up its own regional mental health care plan. That is real institutional recognition, written into the machinery of how medical care gets planned across the country.
Neither the campaign nor the designation created psychiatrists, though. Attitudes and planning documents moved. The number of specialists available per patient did not move with them.
Where the Gap Widens Instead of Closing
The clearest evidence that awareness has outrun capacity sits in the same projection work. Statistical measures of how unevenly psychiatrists are distributed across Japan's prefectures relative to patient need are expected to increase for every major mental illness studied, right through 2045. Unevenness is forecast to get worse, not better, over two decades.
That matters for both barriers at once. A person who overcomes stigma and asks for help still arrives at a system whose geography is becoming less favourable, and whoever writes their first prescription will have less specialist support behind them, not more. The campaigns taught people a new way to talk about depression. The thing they go on to need, when the talking is done, is somebody with the time to get the treatment right.
